http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 05:37:49 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/West+Pharma+%28WST%29+June+calls+active/26625865.html <p>West Pharma (NYSE: WST) 30-day option implied volatility is at 34; compared to its 52-week range of 24 to 64 with a focus on June calls. </p> http://www.streetinsider.com/Options/West+Pharma+%28WST%29+June+calls+active/26625865.html Wed, 10 Jun 2026 05:37:49 -0400 WST http://www.streetinsider.com/Hot+Upgrades/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html (Updated - June 9, 2026 6:26 AM EDT) <p>Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).</p><p>The analyst comments "We upgrade WST to Overweight and increase our price target to $400. When we initiated on the stock at Equal Weight last year, our key reason for staying on the sidelines was mainly around the risk from multi-dose vials to the business, plus the implications of oral GLP-1s coming to market. We admittedly overestimated these potential headwinds and have now done some work that suggests it should not be as http://www.streetinsider.com/Hot+Upgrades/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html Tue, 09 Jun 2026 06:26:27 -0400 WST http://www.streetinsider.com/Upgrades/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html (Updated - June 9, 2026 6:26 AM EDT) <p>Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).</p><p>The analyst comments "We upgrade WST to Overweight and increase our price target to $400. When we initiated on the stock at Equal Weight last year, our key reason for staying on the sidelines was mainly around the risk from multi-dose vials to the business, plus the implications of oral GLP-1s coming to market. We admittedly overestimated these potential headwinds and have now done some work that suggests it should not be as http://www.streetinsider.com/Upgrades/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html Tue, 09 Jun 2026 06:26:27 -0400 WST http://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html (Updated - June 9, 2026 6:26 AM EDT) <p>Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).</p><p>The analyst comments "We upgrade WST to Overweight and increase our price target to $400. When we initiated on the stock at Equal Weight last year, our key reason for staying on the sidelines was mainly around the risk from multi-dose vials to the business, plus the implications of oral GLP-1s coming to market. We admittedly overestimated these potential headwinds and have now done some work that suggests it should not be as http://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html Tue, 09 Jun 2026 06:26:27 -0400 WST http://www.streetinsider.com/Hot+Comments/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html (Updated - June 9, 2026 6:26 AM EDT) <p>Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).</p><p>The analyst comments "We upgrade WST to Overweight and increase our price target to $400. When we initiated on the stock at Equal Weight last year, our key reason for staying on the sidelines was mainly around the risk from multi-dose vials to the business, plus the implications of oral GLP-1s coming to market. We admittedly overestimated these potential headwinds and have now done some work that suggests it should not be as http://www.streetinsider.com/Hot+Comments/Barclays+Upgrades+West+Pharmaceutical+%28WST%29+to+Overweight/26619828.html Tue, 09 Jun 2026 06:26:27 -0400 WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/AI/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html <p>Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.</p><p>The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.</p><p>The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage http://www.streetinsider.com/General+News/Jefferies+finds+AI+drives+up+to+50%25+cost+cuts+in+drug+development/26590151.html Tue, 02 Jun 2026 12:32:48 -0400 CRL IQV MEDP NVDA RTRX SDGR WST http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++WEST+PHARMACEUTICAL+SERV++For%3A+May+31/26584356.html si-local-file:///var/storage/secattach/20260601/26584356.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++WEST+PHARMACEUTICAL+SERV++For%3A+May+31/26584356.html Mon, 01 Jun 2026 16:35:00 -0400 O.00001036 WST http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++WEST+PHARMACEUTICAL+SERV++For%3A+May+31/26584356.html si-local-file:///var/storage/secattach/20260601/26584356.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++WEST+PHARMACEUTICAL+SERV++For%3A+May+31/26584356.html Mon, 01 Jun 2026 16:35:00 -0400 O.00001036 WST http://www.streetinsider.com/New+Coverage/Wolfe+Research+Assumes+West+Pharmaceutical+%28WST%29+at+Outperform/26583319.html (Updated - June 1, 2026 4:31 PM EDT) <p>Wolfe Research analyst Mike Polark assumes coverage on West Pharmaceutical (NYSE: WST) with a Outperform rating.</p><p>The analyst comments "We rate WST shares Outperform and have a $375 target price. This represents 40x our 2027 EPS estimate. A punchy input, we know – we unpack comfort/enthusiasm in subsequent paragraphs. However, relative to a history of premium absolute and relative valuation, this P/E input range isn’t completely offsides: (1) WST’s absolute P/E back ~15-years has average/median of 40x; (2) WST’s average premium to S&P 500 back 15-years is >100%; with S&P 500 here 22x NTM, http://www.streetinsider.com/New+Coverage/Wolfe+Research+Assumes+West+Pharmaceutical+%28WST%29+at+Outperform/26583319.html Mon, 01 Jun 2026 16:31:26 -0400 WST http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Assumes+West+Pharmaceutical+%28WST%29+at+Outperform/26583319.html (Updated - June 1, 2026 4:31 PM EDT) <p>Wolfe Research analyst Mike Polark assumes coverage on West Pharmaceutical (NYSE: WST) with a Outperform rating.</p><p>The analyst comments "We rate WST shares Outperform and have a $375 target price. This represents 40x our 2027 EPS estimate. A punchy input, we know – we unpack comfort/enthusiasm in subsequent paragraphs. However, relative to a history of premium absolute and relative valuation, this P/E input range isn’t completely offsides: (1) WST’s absolute P/E back ~15-years has average/median of 40x; (2) WST’s average premium to S&P 500 back 15-years is >100%; with S&P 500 here 22x NTM, http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Assumes+West+Pharmaceutical+%28WST%29+at+Outperform/26583319.html Mon, 01 Jun 2026 16:31:26 -0400 WST http://www.streetinsider.com/Management+Changes/West+Pharmaceutical+Services+names+Michel+Lagarde+as+new+CEO/26584190.html <p>West Pharmaceutical Services, Inc. (NYSE: WST) announced that its board of directors has appointed Michel Lagarde as president and chief executive officer, effective August 31, 2026. Lagarde will also join the company's board of directors on that date.</p> <p>Lagarde succeeds Eric M. Green, who will retire from his roles as president, CEO and board chair on August 31, 2026. The board elected Lead Independent Director Robert F. Friel to become board chair, also effective August 31, 2026.</p> <p>Lagarde most recently served as executive vice president and chief operating officer at Thermo Fisher Scientific, Inc., where he had responsibility for the majority of http://www.streetinsider.com/Management+Changes/West+Pharmaceutical+Services+names+Michel+Lagarde+as+new+CEO/26584190.html Mon, 01 Jun 2026 16:30:16 -0400 A.50204686 O.00001036 O.00167014 WST http://www.streetinsider.com/Management+Changes/West+Pharmaceutical+Services+names+Michel+Lagarde+as+new+CEO/26584190.html <p>West Pharmaceutical Services, Inc. (NYSE: WST) announced that its board of directors has appointed Michel Lagarde as president and chief executive officer, effective August 31, 2026. Lagarde will also join the company's board of directors on that date.</p> <p>Lagarde succeeds Eric M. Green, who will retire from his roles as president, CEO and board chair on August 31, 2026. The board elected Lead Independent Director Robert F. Friel to become board chair, also effective August 31, 2026.</p> <p>Lagarde most recently served as executive vice president and chief operating officer at Thermo Fisher Scientific, Inc., where he had responsibility for the majority of http://www.streetinsider.com/Management+Changes/West+Pharmaceutical+Services+names+Michel+Lagarde+as+new+CEO/26584190.html Mon, 01 Jun 2026 16:30:16 -0400 A.50204686 O.00001036 O.00167014 WST